| Drug Name |
Etanercept |
| Drug ID |
BADD_D00838 |
| Description |
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA). |
| Indications and Usage |
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis. |
| Marketing Status |
Prescription |
| ATC Code |
L04AB01 |
| DrugBank ID |
DB00005
|
| KEGG ID |
D00742
|
| MeSH ID |
D000068800
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0I5QX
|
| NDC Product Code |
58406-425; 58406-455; 50090-3531; 50090-4490; 58406-055; 58406-010; 58406-044; 58406-021; 58406-435; 50090-4590; 58406-456; 58406-445; 58406-446; 58406-032 |
| Synonyms |
Etanercept | TNFR-Fc Fusion Protein | Fusion Protein, TNFR-Fc | TNFR Fc Fusion Protein | TNR 001 | TNT Receptor Fusion Protein | TNTR-Fc | TNR-001 | TNR001 | Etanercept-szzs | TNF Receptor Type II-IgG Fusion Protein | TNF Receptor Type II IgG Fusion Protein | Erelzi | Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein | Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein | Enbrel |
